This week's roundup of Houston innovators includes Dr. Evan Collins of Houston Methodist, Margarita Kelrikh of Pillsbury, and Howard Berman of Coya Therapeutics. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a new innovator in residency, a Houston startup lawyer, and a neurodegenerative therapeutics CEO.

Evan Collins, innovator in residency at Houston Methodist

Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, was named the hospital's first innovator in residency. Photo via drevancollins.com

Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, is the inaugural innovator in residency at Houston Methodist Center for Innovation.

What does an innovator-in-residency do? Collins sat down with InnovationMap to explain. His role, he explains, is to encourage other clinicians to get involved in the innovation process, particularly using digital health care programs.

“When you look at all the technology, especially the digital technology that's being applied [in medicine], and the future of digital technology, whether you define it as AI or other variations, having a clinical perspective to vet a lot of these possible solutions, as opposed to just keeping it on the administrative side of things, has greater value,” he says. Read more.

Margarita Kelrikh, counsel at Pillsbury

Margarita Kelrikh joins the Houston Innovators Podcast to discuss her career, legal tips for startups, and why she's dedicated to the Houston startup community. Photo courtesy

After working at WeWork and its upstart competitor for several years, Margarita Kelrikh realized it was time to move back into a law firm where she could help more early stage Houston startup clients. She recently joined Pillsbury's Houston office as counsel.

"I realized I wanted to work with the people who I worked with in the past, and the only way I could do that is if I went back to a law firm," she says, explaining that working in house means you can only have one client: your employer. "It's about having that variety and being able to work with a wide array of people."

Kelrikh shares some of her go-to startup legal advice on this week's episode of the Houston Innovators Podcast, and she emphasizes how ready and willing she is to serve the Houston startup community. Read more.

Howard Berman, CEO and co-founder of Coya Therapeutics

Coya Therapeutics is looking into how a trendy weight loss drug could complement its Alzheimer’s disease treatment. Photo via LinkedIn

Glucagon-like peptide 1, or GLP-1, agonists are all the rage right now thanks to drugs like Ozempic and Wegovy. Though they’re currently being prescribed for diabetes and weight loss, a Houston company reports that it may have found another use for GLP-1s.

Coya Therapeutics, a publicly traded clinical-stage biotechnology company, has filed intellectual property protection for a combination of its proprietary COYA 301 and GLP-1. Coya’s team believes that combining COYA 301, a low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs), with GLP-1 could be a game-changer in the fight against Alzheimer’s disease.

According to Coya’s CEO, Howard Berman, “We believe that combination immunotherapy approaches will evolve to play a meaningful role in treating complex immune-based diseases that are driven by a host of pathophysiologic mechanisms.” Read more.

Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, was named the hospital's first innovator in residency. Photo via drevancollins.com

Houston Methodist names orthopedic surgeon as inaugural innovator in residency

leading medicine

Houston Methodist Center for Innovation has named its first innovator in residency.

Roberta Schwartz, executive vice president and chief innovation officer at Methodist, chose Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, for the role.

“Dr. Collins has been a physician champion for innovation projects over the past few years and will be an exceptional asset for our team to help involve physicians more actively in innovation throughout our hospital system,” Schwartz wrote on LinkedIn.

So what does an innovator-in-residency do? Collins sat down with InnovationMap to explain.

“When you look at all the technology, especially the digital technology that's being applied [in medicine], and the future of digital technology, whether you define it as AI or other variations, having a clinical perspective to vet a lot of these possible solutions, as opposed to just keeping it on the administrative side of things, has greater value,” he says.

His role, he explains, is to encourage other clinicians to get involved in the innovation process, particularly using digital health care programs. “Innovating is great, but the information that's coming has to be actionable in a way that fits a business model and answers significant questions in health care,” says the New York native.

He uses the metaphor of an Apple Watch’s sleep tracker to illustrate what is perhaps less than actionable. After all, you wake up knowing if you slept well without a device telling you about the quality of your night’s rest. His job, then, is vetting opportunities and technologies with the goal of deciding what may make a good return on its investment.

“‘Does it increase my capacity to see patients? Does it improve things in a meaningful way?’,” he asks. “It's looking at the opportunities within health care, but applying some rigor to it from a clinical perspective to vet, ‘Is this really going to give us actionable information where we can create value when this thing is produced?’”

Collins jokes that he was chosen for the role because he “got the short straw.” But his background speaks for itself. He’s been at Methodist for 27 years and received his MBA from Rice University’s Jesse H. Jones Graduate School of Business in 2013. He’s used his expertise to improve efficiency in the operating room, allowing him to help more patients than ever before.

“Maybe they saw this as another opportunity to give input that could be helpful and contribute to the organization and I'm grateful for that opportunity,” says Collins. The “they” he’s referring to is Schwartz, but also Marc L. Boom, Methodist’s forward-thinking president and CEO. “They recognize the importance of what we're trying to do here for the future of health care. So I think I'm grateful for that opportunity, but they are the ones that create that opportunity for me to contribute.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines strikes $49.3M deal to expand lunar communications network

space deal

Houston-based Intuitive Machines is bulking up its space-to-ground data network with the acquisition of United Kingdom-based Goonhilly Earth Station and its U.S. arm, COMSAT.

The $49.3 million cash-and-stock deal would add 44 antennas to Intuitive Machines’ network. The acquisition is expected to close in the third quarter.

Intuitive Machines, a space infrastructure and services company, designs, builds, and operates spacecraft and data networks for lunar and deep-space missions. Goonhilly operates a satellite Earth station in Cornwall, England.

Intuitive Machines says Goonhilly’s and COMSAT’s civil, commercial, and government customers will complement its current customer base and broaden its reach into related sectors.

“Customers have been clear that they want a single, integrated, and resilient solution for their communications and [position, navigation, and timing] needs as they accelerate missions at an unprecedented pace,” Steve Altemus, co‑founder and CEO of Intuitive Machines, said in a news release.

Kenn Herskind, executive chairman of Goonhilly, says the acquisition “will allow us to scale that capability globally and directly support the next era of lunar exploration. Together, we will be creating a commercial lunar communications network that is interoperable, resilient, and ready to support Artemis and international missions.”

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.